Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity
A phase II study presented at the American Society of Hematology annual meeting showed that a chemotherapy-free combination of ponatinib and blinatumomab for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia led to high rates of deep minimal residual disease negativity and durable remissions without the need for stem cell transplant in most patients. The 3-year overall survival rate was 88%, with only two of 76 patients requiring transplant. Predictors of relapse included elevated white blood cell count, VPREB1 deletion, and CNS disease at diagnosis.
Highlighted Terms
Related News
A phase II study presented at the American Society of Hematology annual meeting showed that a chemotherapy-free combination of ponatinib and blinatumomab for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia led to high rates of deep minimal residual disease negativity and durable remissions without the need for stem cell transplant in most patients. The 3-year overall survival rate was 88%, with only two of 76 patients requiring transplant. Predictors of relapse included elevated white blood cell count, VPREB1 deletion, and CNS disease at diagnosis.